2024-11-07 11:10:39 :
Neuland Laboratories Second Quarter Results Live: Neuland Laboratories reported second quarter results on November 6, 2024, with both revenue and profits declining significantly. The company’s revenue fell by 25.59% year-on-year, and its profits dropped significantly by 63.2% compared with the same period last year.
In addition to the year-on-year decline, Neuland’s revenue also fell by 29.29% from the previous quarter, and profits fell by 66.44%. The sharp decline has raised concerns among investors about the company’s performance in a competitive market.
Despite the decrease in expenses, the company’s selling, general and administrative (SG&A) expenses fell 13.77% month-on-month and 8.54% year-on-year. However, this was not enough to offset the decline in revenue and profits.
Operating income also declined significantly in the second quarter, down 63.86% month-on-month and 62.47% year-on-year. This trend illustrates the ongoing challenge of maintaining profitability amid volatile market conditions.
Earnings per share (EPS) for the quarter were $25.6, a decrease of 63.2% from the previous year. The reduction further highlights the pressure Neuland Laboratories faces in a tough economic climate.
On a more positive note, Neuland Laboratories has returned 2.43% over the past week and an impressive 89.94% over the past six months, with a year-to-date return of 167.7%, demonstrating long-term resilience.
Currently, Neuland Laboratories has a market capitalization of $Rs 18,173.86 Crore, a new 52-week high $16,524.95 minimum $4,718, indicating significant fluctuations in its share price.
Of the two analysts covering the company as of November 7, 2024, one has a Buy rating and another has a Strong Buy rating. Consensus recommendations reflect a Strong Buy so far, suggesting analysts remain optimistic despite the recent decline.
Neulan Laboratories financial status
| period | Q2 | Q1 | month-on-month growth | Q2 | year-on-year growth |
|---|---|---|---|---|---|
| total revenue | 310.84 | 439.6 | -29.29% | 417.75 | -25.59% |
| Total Selling/General/Administrative Expenses | 63.07 | 73.14 | -13.77% | 68.96 | -8.54% |
| Depreciation/Amortization | 16.07 | 16.28 | -1.26% | 14.51 | +10.8% |
| total operating expenses | 264.69 | 311.9 | -15.14% | 294.77 | -10.2% |
| operating income | 46.15 | 127.71 | -63.86% | 122.98 | -62.47% |
| net income before tax | 49.42 | 129.84 | -61.94% | 121.59 | -59.35% |
| net income | 32.84 | 97.87 | -66.44% | 89.25 | -63.2% |
| Diluted normalized earnings per share | 25.6 | 64.16 | -60.1% | 69.56 | -63.2% |
Follow us On Social Media   Twitter/X
